ArticleJournal of vascular and interventional radiology : JVIR2026
Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.
Article in Journal of vascular and interventional radiology : JVIR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo evaluate the safety and effectiveness of irreversible electroporation (IRE) as salvage therapy for locally advanced pancreatic cancer (LAPC). MATERIALS AND
methodsA retrospective cohort study was conducted of IRE performed by interventional radiologists or hepatopancreaticobiliary surgeons at a tertiary care institution for salvage treatment of LAPC. Procedures were performed between 2010 and 2024; 30 subjects (men, 18; women, 12; median age, 63.5 years) with biopsy-proven adenocarcinoma, evidence of vascular encasement, and progression on chemotherapy were included. Data were collected for patient demographics, prior treatments, tumor size, carbohydrate antigen (CA)19-9 levels, length of treatment stay, IRE treatment parameters, adverse events, posttreatment therapies, overall survival (OS), and progression-free survival (PFS).
resultsOf 30 patients, 14 received percutaneous IRE and 16 received surgical IRE. Nine subjects received palliative surgery with IRE. OS was 11.4 months (IQR, 6-28 months). PFS was 7.6 months (IQR, 4-21 months). The overall adverse event rate was 33.3%. The serious adverse event rate was 12.1%. There was no association between survival or adverse event rate and age, tumor size, tumor location, or CA19-9 level. Moreover, 50% of subjects received additional treatment following IRE. OS for IRE with chemotherapy was 20.4 months. Outcome and adverse event rate were similar regardless of prior radiation treatment.
conclusionsThis study demonstrates that IRE may be a safe and effective option for salvage treatment of LAPC following chemotherapy and radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.